Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celsion Corporation    CLSN

CELSION CORPORATION

(CLSN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

CLSN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Corporation Shareholders With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: December 28, 2020

11/13/2020 | 11:01am EST

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against of Celsion Corporation ("Celsion" or "the Company") (NASDAQ: CLSN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Celsion securities between November 2, 2015 to July 10, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/clsn.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants had significantly overstated the efficacy of ThermoDox; (2) the foregoing significantly diminished the approval and commercialization prospects for ThermoDox; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/clsn or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Celsion you have until December 28, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.


© Business Wire 2020
All news about CELSION CORPORATION
01/26CELSION : Raises Net Proceeds of $32.6 Million from Registered Direct Offering
MT
01/26Celsion corporation announces closing of $35 million registered direct offeri..
GL
01/25CELSION CORP : Entry into a Material Definitive Agreement, Other Events, Financi..
AQ
01/22MIDDAY REPORT : Wall Street Drifts Lower Midday as IBM, Intel Slump
MT
01/22CELSION : to Raise $35 Million in Registered Direct Offering of Common Stock
MT
01/22Celsion corporation announces $35 million registered direct offering priced a..
GL
01/21CELSION CORP : Termination of a Material Definitive Agreement (form 8-K)
AQ
2020CELSION CORP : Change in Directors or Principal Officers (form 8-K)
AQ
2020DEADLINE TODAY : The Schall Law Firm Announces it is Investigating Claims Agains..
BU
2020CELSION : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
More news
Financials (USD)
Sales 2020 0,50 M - -
Net income 2020 -23,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -2,44x
Yield 2020 -
Capitalization 66,6 M 66,6 M -
Capi. / Sales 2020 133x
Capi. / Sales 2021 -
Nbr of Employees 29
Free-Float 98,8%
Chart CELSION CORPORATION
Duration : Period :
Celsion Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELSION CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 3,00 $
Last Close Price 1,78 $
Spread / Highest target 68,5%
Spread / Average Target 68,5%
Spread / Lowest Target 68,5%
EPS Revisions
Managers and Directors
NameTitle
Michael H. Tardugno Chairman, President & Chief Executive Officer
Jeffrey Wayne Church CFO, Secretary & SVP-Investor Relations
Nicholas Borys Chief Medical Officer & Senior Vice President
Khursheed Anwer Chief Scientific Officer & Executive VP
Pok Yu Chow Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELSION CORPORATION150.35%67
GILEAD SCIENCES, INC.14.49%85 440
WUXI APPTEC CO., LTD.36.65%68 869
VERTEX PHARMACEUTICALS0.55%62 750
REGENERON PHARMACEUTICALS12.62%57 859
BEIGENE, LTD.38.68%34 368